A team of Stanford engineers has identified first-in-class epidermal growth factor (EGF) mutants with enhanced activity. These mutants can stimulate increased EGF receptor activation at 10-fold lower concentrations than wild-type EGF.
Stanford inventors have found that Stanniocalcin 2 (STC2) treatment following stoke leads to improved functional recovery and a pharmaceutical composition containing STC2 as an active ingredient can be used to facilitate post stroke recovery.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Stanford researchers in the Weissman lab have developed an engineered protein that blocks the function of the CD47 mimics pathogens use to evade the immune system.
Cherpes Lab investigators discovered that recombinant ephrin-A3 or agonist ephrin-A3-derived peptides promote expression of cell-cell adhesion molecules in epithelial surfaces and improve epithelial barrier function.
Stanford researchers at the Sattely Lab have discovered six podophyllotoxin biosynthetic genes and their polypeptide products from the plant, Podophyllum hexandrum (mayapple).
Researchers in Dr. Karl Deisseroth's lab have engineered a channelrhodopsin variant that can be stimulated by red light and has fast stimulation frequencies. In neurons, channelrhodopsins are light activated protein channels that induce action potential firing.
FragFEATURE is a data-driven computational method for fragment binding prediction. It predicts small molecule fragments preferred by a protein structure using a knowledge base of all previously observed protein-fragment interactions.
Druggability of a protein is its potential to be modulated by drug-like molecules. It is important in the target selection phase. We developed DrugFEATURE to quantify druggability by assessing the microenvironments in potential small-molecule binding sites.
Researchers in Dr. Bingwei Lu's lab have identified genes that could serve as therapeutic targets for the treatment of Parkinson's disease (PD). PD is a common neurodegenerative movement disorder affecting 1% of the population over the age 60.
Stanford researchers have developed a highly specific, tunable system to improve the safety, efficacy and deliverability of gene therapy vectors and other biological therapies.